Wells Fargo & Company Sage Therapeutics, Inc. Transaction History

Wells Fargo & Company

$429 Billion
Q1 2025

A detailed history of Wells Fargo & Company transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 34,042 shares of SAGE stock, worth $222,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,042

Previous 33,051 3.0%

Holding current value

$222,294

Previous $179,000 50.84%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$5.55 - $8.66 $5,500 - $8,582	991 Added 3.0%	34,042 $270,000
Q4 2024 Feb 12, 2025	BUY	$4.78 - $8.57 $33,875 - $60,735	7,087 Added 27.3%	33,051 $179,000
Q3 2024 Nov 13, 2024	BUY	$7.02 - $13.08 $8,859 - $16,506	1,262 Added 5.11%	25,964 $187,000
Q2 2024 Aug 13, 2024	BUY	$10.58 - $17.9 $78,080 - $132,102	7,380 Added 42.6%	24,702 $268,000
Q1 2024 May 10, 2024	BUY	$18.62 - $26.95 $26,440 - $38,269	1,420 Added 8.93%	17,322 $324,000
Q4 2023 Feb 09, 2024	SELL	$17.1 - $22.26 $1.23 Million - $1.61 Million	-72,207 Reduced 81.95%	15,902 $344,000
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $564,140 - $1.65 Million	33,680 Added 61.88%	88,109 $1.81 Million
Q2 2023 Aug 15, 2023	BUY	$40.65 - $59.54 $129,836 - $190,170	3,194 Added 6.23%	54,429 $2.56 Million
Q1 2023 May 12, 2023	BUY	$37.27 - $46.57 $1.55 Million - $1.93 Million	41,512 Added 426.95%	51,235 $2.15 Million
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $85,780 - $116,177	-2,664 Reduced 21.51%	9,723 $370,000
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $316,828 - $424,695	9,815 Added 381.61%	12,387 $485,000
Q2 2022 Aug 12, 2022	BUY	$27.52 - $37.99 $28,070 - $38,749	1,020 Added 65.72%	2,572 $83,000
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $9,397 - $13,987	306 Added 24.56%	1,552 $52,000
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $2.71 Million - $3.44 Million	-73,097 Reduced 98.32%	1,246 $53,000
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $2.01 Million - $2.87 Million	-49,993 Reduced 40.21%	74,343 $3.29 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $1.14 Million - $1.65 Million	20,820 Added 20.11%	124,336 $7.06 Million
Q1 2021 May 13, 2021	SELL	$70.65 - $96.76 $158,326 - $216,839	-2,241 Reduced 2.12%	103,516 $7.75 Million
Q4 2020 Feb 09, 2021	SELL	$58.41 - $89.06 $2.24 Million - $3.41 Million	-38,308 Reduced 26.59%	105,757 $9.15 Million
Q3 2020 Nov 05, 2020	BUY	$41.13 - $62.45 $600,045 - $911,083	14,589 Added 11.27%	144,065 $8.81 Million
Q2 2020 Aug 13, 2020	BUY	$25.95 - $43.15 $363,663 - $604,704	14,014 Added 12.14%	129,476 $5.38 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $3.02 Million - $8.92 Million	115,462 New	115,462 $3.32 Million

Others Institutions Holding SAGE

# of Institutions

217

Shares Held

49.9M

Call Options Held

220K

Put Options Held

312K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $388M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Sage Therapeutics, Inc. Transaction History